


# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★	110.97 USD	118.00 USD	0.94	2.02	2.09	149.19	Medical Devices	Standard
23 Nov 2020 22:19, UTC	23 Nov 2020	18 Feb 2020 20:20, UTC		23 Nov 2020	23 Nov 2020	23 Nov 2020		

Morningstar Pillars	Analyst	Quantitative
Economic Moat	Wide	Wide
Valuation	★★★	Fairly Valued
Uncertainty	Medium	Medium
Financial Health	—	Moderate

Source: Morningstar Equity Research

## Quantitative Valuation



	Current	5-Yr Avg	Sector	Country
Price/Quant Fair Value	1.00	0.97	0.82	0.90
Price/Earnings	34.0	34.0	26.5	17.4
Forward P/E	27.5	—	11.3	13.0
Price/Cash Flow	25.0	19.6	18.4	13.1
Price/Free Cash Flow	31.5	23.8	27.3	19.3
Trailing Dividend Yield%	2.02	2.10	1.50	1.92

Source: Morningstar

## Bulls Say

- ▶ Medtronic has historically held roughly 50% share in its core heart devices. It's also the market leader in spinal products, insulin pumps, and neuromodulators for chronic pain.
- ▶ Medtronic's pipeline contains treatments for atrial fibrillation, mitral valve disease, and renal denervation for hypertension. If these new therapies prove effective, Medtronic could dominate three more potentially large markets.
- ▶ Medtronic often finds novel ways to apply familiar technologies, like using the implantable electronic stimulation in pacemakers to address fecal incontinence and chronic pain.

## Bears Say

- ▶ As smaller firms introduce new insulin pump technology, Medtronic may face a stiffer fight to maintain its leadership in this arena.
- ▶ Medtronic's devices are indirectly subject to Medicare reimbursement rates; increasing pressure on payments could hurt profitability.
- ▶ Over the years, Medtronic has issued a number of voluntary recalls of some of its products. Although the fatalities associated with these problems have remained extremely low, recalls generally require time and effort and can hurt doctors' confidence in the products.

## Important Disclosure:

The conduct of Morningstar's analysts is governed by Code of Ethics/Code of Conduct Policy, Personal Security Trading Policy (or an equivalent of), and Investment Research Policy. For information regarding conflicts of interest, please visit <http://global.morningstar.com/equitydisclosures>

## Medtronic Displays Some Unexpected Strength in Fiscal Second Quarter; Holding Steady on Our FVE

### Business Strategy and Outlook

Debbie S. Wang, Sr. Eq. Analyst, 18 February 2020

Medtronic's standing as the largest pure-play medical device maker remains a force to be reckoned with in the med-tech landscape. Pairing Medtronic's diversified product portfolio aimed at a wide range of chronic diseases with its expansive selection of products for acute care in hospitals has bolstered Medtronic's position as a key partner for its hospital customers.

Medtronic has historically focused on innovation, designing and manufacturing devices to address cardiac care, neurological and spinal conditions, and diabetes. All along, the firm has remained focused on its fundamental strategy of innovation. It is often first to market with new products and has invested heavily in internal research and development efforts as well as acquiring emerging technologies. However, in the postreform healthcare world where there are higher hurdles for securing reimbursement for next-generation technology, Medtronic has slightly shifted its strategy to focus on partnering more closely with its hospital clients by offering greater breadth of products and services to help hospitals operate more efficiently. By partnering more closely and integrating itself into more hospital operations, Medtronic is well positioned to take advantage of more business opportunities in the value-based reimbursement environment, in our view. In particular, Medtronic has been pioneering risk-based contracting around some of its cardiac and diabetes products, which we think is attractive to hospital clients and payers alike.

We have always appreciated Medtronic's diverse portfolio, where certain waning product lines would be offset by growth in other categories. The addition of devices and consumables used in the surgical suite should further stabilize potential speed bumps in individual product lines. Medtronic continues to focus on penetrating emerging markets, especially China. We estimate Medtronic generated nearly \$2 billion in Chinese sales in fiscal 2019. Medtronic's broad portfolio of products fits well with the firm's earlier purchase of Kanghui Holdings, which provides the firm with an established network of native distributors that can reach

thousands of hospitals in China.

### Analyst Note

Debbie S. Wang, Sr. Eq. Analyst, 24 November 2020

Medtronic reported fiscal second-quarter results that displayed some pockets of unexpected strength, but the company generally remains on track to meet our full-year expectations, and we're standing behind our fair value estimate. At this point, we think the shares are fairly valued. As seen with rival firms, Medtronic benefited from consistent sequential improvement this fall following the nadir last spring. Though nonpandemic procedure volume recovered through the summer, the latest upward trend in COVID-19 viral transmission leaves us cautious about the next two quarters, especially if hospitals become filled with pandemic patients. This quarter's performance underscores our confidence in Medtronic's wide economic moat, which is supported by intangible assets and the ability to innovate.

Second-quarter revenue declined year over year just 1.5% in constant currency, which was a favorable contrast to the 17% decrease seen in the fiscal first quarter. Further, the firm kept a tight hold on expenses, which remain in line with our projections. Not surprisingly, the standout this quarter was the respiratory, gastrointestinal, and renal product line, which grew 30% thanks to strong demand for Medtronic's relatively sophisticated ventilators. We were pleasantly surprised to also see strength in unexpected areas, including core spine, neuromodulation, and cardiac rhythm and heart failure—all of which were down in the low single digits in second quarter. This is particularly noteworthy as spine and neuromodulation are considerably more elective than many of the cardiac procedures. Importantly, the improved sales were largely driven by Medtronic's suite of new products that offer meaningful innovation, including the Mazor robot, a new mechanism for spinal cord stimulation, and continued adaptation of its leadless pacemaker.

### Economic Moat

Debbie Wang, Sr. Eq. Analyst, 18 February 2020

Medtronic's wide moat is rooted in its dominant presence in highly engineered medical devices to treat chronic

# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★	110.97 USD	118.00 USD	0.94	2.02	2.09	149.19	Medical Devices	Standard
23 Nov 2020 22:19, UTC	23 Nov 2020	18 Feb 2020 20:20, UTC		23 Nov 2020	23 Nov 2020	23 Nov 2020		

Close Competitors	Currency (Mil)	Market Cap	TTM Sales	Operating Margin	TTM/PE
Johnson & Johnson JNJ	USD	378,744	80,856	24.66	22.62
Boston Scientific Corp BSX	USD	47,726	10,108	9.20	12.77

diseases, including those beyond its historical stronghold in heart disease. Medtronic's moat comes from several sources.

In the cardiac area, Medtronic competes with roughly three competitors in total across its heart-related portfolio. The markets for pacemakers, ICDs, coronary stents, heart valves, and neuromodulation generally operate as rational oligopolies. There are some switching costs related to cardiac rhythm management devices and transcatheter aortic heart valves.

In the spine area, Medtronic's moat is strengthened by high switching costs for surgeons. Doctors often rely on medical device sales reps for their deep device knowledge as well as their experience with device usage in a wide range of patients. As a result, Medtronic's reps play the role of highly specialized experts who advise practitioners on implantation, programming, and maintenance of Medtronic devices and create sticky relationships with medical practitioners. This dynamic tends to keep spinal surgeons loyal to Medtronic's products, as long as the company does not fall too far behind its competitors when it comes to introducing new technology.

Finally, Medtronic's wide moat is bolstered by several intangibles, including intellectual property and carefully nurtured relationships with physicians. Thanks to its persistent ability to innovate, Medtronic is often first to market with new products in various therapeutic areas. We expect Medtronic to continue its record of innovation, based on its extensive patent portfolio. According to independent intellectual property evaluation publications Device Link and The Patent Board, Medtronic holds the strongest intellectual property position based on number and technological strength of its patents.

We think Medtronic's diversified medical technology portfolio allows it to better weather occasional glitches in the development or approval process for any particular new device. Investments in neuromodulation, diabetes, and spinal products from the middle to late 1990s paid off in spades through 2010. Although the spine and ICD

businesses have been hit with slower market growth since then, the firm has seen double-digit growth in its diabetes, surgical technologies, drug-coated balloons, neurovascular, and atrial fibrillation segments. While some of Medtronic's product lines have waned as new clinical data has altered treatment guidelines, the firm continues to invest in emerging technologies, including renal denervation and transcatheter mitral valves, that should drive future growth.

The addition of Covidien deepens Medtronic's competitive advantages, as Covidien's medical device segment enjoys brand recognition, technological innovation, and substantial scale. Covidien's innovation record, enhanced by incremental research investment during the past few years, has resulted in a steady stream of product upgrades and new technologies. Most of Covidien's device subsegments operate in an oligopolistic fashion; the absence of irrational price competition and the evolutionary (rather than revolutionary) nature of innovation tend to lead to only marginal share shifts in the industry and strong excess returns. Covidien currently ranks at or near the top in all product categories where it competes in devices and vies mainly with Johnson & Johnson; the rest of the field is typically highly fragmented, with most companies occupying product niches rather than competing broadly against the big two.

We have seen no new entrants making significant inroads. New competitors sometimes pop up on the margins, ranging from less sophisticated (discounted prices) to high-end (technological advancements), but they rarely result in monumental market shifts. The existing players' positioning is very defensible, with most practitioners rarely switching to competitors' products because of inertia as well as up-front training costs. While surgeons' influence over procurement decisions is arguably waning, the established players also have administrators' ears. Covidien and J&J dominate a number of surgical specialties with the breadth of their portfolios, rendering competitors' efforts to displace them on cost on an individual product basis less meaningful.

## Fair Value & Profit Drivers

Debbie Wang, Sr. Eq. Analyst, 18 February 2020

We're increasing our fair value estimate to \$118 per share, up from \$110, after incrementally raising our long-term assumption for earnings growth by 50 basis points to reflect the firm's strong new product pipeline. We

# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★	110.97 USD	118.00 USD	0.94	2.02	2.09	149.19	Medical Devices	Standard
23 Nov 2020 22:19, UTC	23 Nov 2020	18 Feb 2020 20:20, UTC		23 Nov 2020	23 Nov 2020	23 Nov 2020		

continue to incorporate fairly optimistic expectations for innovation in the structural heart, diabetes, and neurovascular units, as well as gradual margin expansion to account for efficiency programs and higher-margin new products.

We project 4% average annual top-line growth through fiscal 2024. We expect Medtronic's new neuromodulation indications, drug-eluting balloons and insulin pumps, ongoing development of the atrial fibrillation market, and transcatheter valve sales to defend against pricing erosion in the near term. We estimate slightly faster 5.5% average annual revenue growth from the restorative therapies group through fiscal 2024, driven by adoption of new technologies in neuromodulation and neurovascular and a return to growth of the spine business thanks to the addition of the Mazor robot.

While legacy Medtronic's gross margins have historically held firm at about 75%, the addition of Covidien has lowered this by roughly 600 basis points, and the firm has made gradual and steady progress in raising gross margin more than 100 basis points over the last four years. We think the company can eke out incremental improvement over the next few years as it further rationalizes its manufacturing assets. We project normalized gross margin at roughly 70% over the longer term. We expect further cost synergies to emerge from sales and administration, thanks to more cross-selling and bundling of products and services.

## Risk & Uncertainty

Debbie Wang, Sr. Eq. Analyst, 18 February 2020

Based on the average volatility of cash flows from a diverse product portfolio in relatively less discretionary therapeutic markets, we rate Medtronic's uncertainty as medium.

With baby boomers hitting Medicare age, there could be future cuts to Medicare reimbursement for device-related procedures, which would translate into financial pressure for its hospital customers. Innovation is the name of the game in medical devices, but the bar has been raised in the wake of healthcare reform. Successfully securing price premiums for new technology is no longer a given and now depends on favorable clinical data. Increasing regulatory attention and interest in conducting more extensive clinical trials and aftermarket studies could increase development costs for Medtronic. Product recall

and liability and inventory write-downs are occasional sore spots for the industry. Although the U.S. Department of Justice wrapped up its investigation into off-label use of the Infuse product without issuing any charges, the controversy around the investigation added uncertainty and contributed to a decline in Infuse sales. Potential investigations into other products and their marketing remain a risk in the medical device business.

## Stewardship

Debbie Wang, Sr. Eq. Analyst, 18 February 2020

In 2011, Omar Ishrak left GE Healthcare to lead Medtronic as CEO and chairman. While he had little direct experience with the cardiac market or the device industry, he was considered a rising star at GE. Ishrak was the pioneer behind GE Healthcare's successful entrance into the China market—he led efforts to expand the product portfolio in order to compete head to head with local Chinese imaging companies such as Mindray, which gave GE a substantial leg up in the midmarkets in China. Considering that Medtronic has been making a number of investments in China and India and has identified emerging markets as a strategic source of growth, we think Ishrak brings valuable perspective to the party. We think he has successfully pushed Medtronic away from its U.S.-centric past and focused the organization more closely on the potential in emerging markets. He has led the firm to invest in new areas of innovation, including transcatheter mitral valve technologies, renal denervation, and spine robotics. Importantly, he's been the driving force behind Medtronic's efforts to position new products and services to help hospital customers improve outcomes and lower costs—key priorities that have shifted hospital purchasing behavior in the wake of the Affordable Care Act.

Now that Ishrak is on the cusp of stepping down, we expect his successor, president Geoff Martha, to continue the firm's focus on innovation. He brings extensive healthcare experience from his GE Healthcare days, as well as the time he has spent on Medtronic's restorative therapies group. Martha also has substantial experience in business development, which leads us to believe he'll continue Medtronic's engagement in ongoing mergers to complement internal innovation.

We think the addition of former sell-side analyst Mike Weinstein to lead corporate strategy is a very intriguing move by Medtronic. We believe Weinstein will bring a deep well of med-tech expertise and connections in the

# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★ 23 Nov 2020 22:19, UTC	110.97 USD 23 Nov 2020	118.00 USD 18 Feb 2020 20:20, UTC	0.94	2.02 23 Nov 2020	2.09 23 Nov 2020	149.19 23 Nov 2020	Medical Devices	Standard

industry, which CFO Karen Parkhill lacks as she came from a banking background. We expect that Weinstein will sharpen Medtronic's focus on M&A activities, help streamline the portfolio (including the potential sale of some products or businesses), and influence and clarify the firm's approach to capital allocation.

Under Ishrak's leadership, management's capital-allocation decisions have been primarily solid, with an occasional misstep when it comes to acquisitions. Like the other major medical device companies, Medtronic makes regular acquisitions of smaller (often privately held) firms that offer emerging technology. These purchases are typically dilutive in the short term because the technology still requires much development to reach commercialization. Though it is difficult to assess the value of what was purchased, we tend to view these investments akin to the internal investments that Medtronic must make in R&D. Our main concern is that, even though Medtronic has not seen a pattern of goodwill impairment, in the past it has not hesitated to pony up generous offers for certain acquisition targets that did not seem to add value over the longer term. For example, Medtronic spent \$4.2 billion to purchase Kyphon in 2008--an acquisition that turned out to be a disappointment as there were fewer-than-expected synergies in terms of sales, marketing, and physician relationships. Medtronic has not been able to goose Kyphon's products back into robust growth. However, we think many of Medtronic's other acquisitions should add value over time, including Mazor, Covidien, and Ardian.

# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★ 23 Nov 2020 22:19, UTC	110.97 USD 23 Nov 2020	118.00 USD 18 Feb 2020 20:20, UTC	0.94	2.02 23 Nov 2020	2.09 23 Nov 2020	149.19 23 Nov 2020	Medical Devices	Standard

## Analyst Notes Archive

### Despite Pandemic Pressures, Medtronic Sees Sequential Easing in Fiscal First Quarter

Debbie Wang, Sr. Eq. Analyst, 25 August 2020

Medtronic's fiscal first-quarter results were tough but not far off from our expectations, and we're leaving our fair value estimate unchanged. The delays in non-pandemic-related procedures took its toll in the fiscal first quarter, with key product lines coronary and structural heart, as well as surgical innovations, falling 15% and 22% (in constant currency), respectively. Similar to other medical device firms, Medtronic saw consistent recovery and smaller losses through its first quarter, after procedure declines bottomed out in April. For example, cardiac rhythm and heart failure, which declined 38% in the fiscal fourth quarter that included April, saw a more moderate year-over-year decrease of 9% in the first quarter. We see little to change our assessment of Medtronic's wide economic moat, though.

While Medtronic's quarterly revenue was down 12% in constant currency year over year, it was up 8.5% sequentially, and we expect further recovery in the next two quarters. Not surprisingly, quarterly operating margin dipped to 10%, which is well below its normal range in the mid to high teens. Nonetheless, it was a vast improvement from 5% in the fiscal fourth quarter. We noted the firm's decision to increase R&D spending, even as the pandemic has pressured revenue growth. Medtronic has the financial flexibility to make these long-term investments, and we expect they will bolster the firm's moat down the line through the launch of novel innovation. We're particularly intrigued by its pipeline products, including the extravascular implantable cardioverter defibrillators, which can bypass the need to implant leads inside the heart chamber, and the pulse ablation system for atrial fibrillation that offers a more targeted approach that reduces the likelihood of collateral damage to tissue. Now that Medtronic has grown so large, ongoing investment to support a wide variety of technologies is critical to keep this company in good health.

### Medtronic Displays Some Unexpected Strength in Fiscal Second Quarter; Holding Steady on Our FVE

Debbie Wang, Sr. Eq. Analyst, 24 November 2020

Medtronic reported fiscal second-quarter results that

displayed some pockets of unexpected strength, but the company generally remains on track to meet our full-year expectations, and we're standing behind our fair value estimate. At this point, we think the shares are fairly valued. As seen with rival firms, Medtronic benefited from consistent sequential improvement this fall following the nadir last spring. Though nonpandemic procedure volume recovered through the summer, the latest upward trend in COVID-19 viral transmission leaves us cautious about the next two quarters, especially if hospitals become filled with pandemic patients. This quarter's performance underscores our confidence in Medtronic's wide economic moat, which is supported by intangible assets and the ability to innovate.

Second-quarter revenue declined year over year just 1.5% in constant currency, which was a favorable contrast to the 17% decrease seen in the fiscal first quarter. Further, the firm kept a tight hold on expenses, which remain in line with our projections. Not surprisingly, the standout this quarter was the respiratory, gastrointestinal, and renal product line, which grew 30% thanks to strong demand for Medtronic's relatively sophisticated ventilators. We were pleasantly surprised to also see strength in unexpected areas, including core spine, neuromodulation, and cardiac rhythm and heart failure--all of which were down in the low single digits in second quarter. This is particularly noteworthy as spine and neuromodulation are considerably more elective than many of the cardiac procedures. Importantly, the improved sales were largely driven by Medtronic's suite of new products that offer meaningful innovation, including the Mazor robot, a new mechanism for spinal cord stimulation, and continued adaptation of its leadless pacemaker.



# Medtronic PLC MDT ★★★<sup>Q</sup> 24 Nov 2020 02:00 UTC

## Last Close

23 Nov 2020

110.97

## Fair Value<sup>Q</sup>

24 Nov 2020 02:00 UTC

110.78

## Market Cap

23 Nov 2020

149.2 Bil

## Sector

Healthcare

## Industry

Medical Devices

## Country of Domicile

IRL Ireland


There is no one analyst in which a Quantitative Fair Value Estimate and Quantitative Star Rating are attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, visit <http://global.morningstar.com/equitydisclosures>

## Company Profile

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

## Quantitative Scores

		Scores		
		All	Rel Sector	Rel Country
Quantitative Moat	Wide	100	100	99
Valuation	Fairly Valued	17	15	33
Quantitative Uncertainty	Medium	99	99	84
Financial Health	Moderate	83	59	60



Source: Morningstar Equity Research

## Valuation

	Current	5-Yr Avg	Sector Median	Country Median
Price/Quant Fair Value	1.00	0.97	0.82	0.90
Price/Earnings	34.0	34.0	26.5	17.4
Forward P/E	27.5	—	11.3	13.0
Price/Cash Flow	25.0	19.6	18.4	13.1
Price/Free Cash Flow	31.5	23.8	27.3	19.3
Trailing Dividend Yield %	2.02	2.10	1.50	1.92
Price/Book	3.0	2.5	3.4	1.7
Price/Sales	5.4	4.1	4.2	1.9

## Profitability

	Current	5-Yr Avg	Sector Median	Country Median
Return on Equity %	8.8	7.9	12.4	13.5
Return on Assets %	4.8	4.2	6.2	6.1
Revenue/Employee (K)	310.3	332.6	309.2	296.5


## Financial Health

	Current	5-Yr Avg	Sector Median	Country Median
Distance to Default	0.6	0.7	0.6	0.7
Solvency Score	445.6	—	494.6	451.9
Assets/Equity	1.8	1.9	1.4	1.8
Long-Term Debt/Equity	0.4	0.5	0.1	0.4

## Growth Per Share

	1-Year	3-Year	5-Year	10-Year
Revenue %	-5.4	-0.9	7.4	6.2
Operating Income %	-21.3	-4.5	2.8	1.1
Earnings %	3.8	7.0	8.0	2.4
Dividends %	8.0	7.9	12.1	10.2
Book Value %	1.3	1.1	0.2	11.0
Stock Total Return %	2.2	12.5	9.5	14.0

## Price vs. Quantitative Fair Value




	2016	2017	2018	2019	2020	TTM	Financials (Fiscal Year in Mil)
Revenue	28,833	29,710	29,953	30,557	28,913	27,927	Revenue
% Change	42.3	3.0	0.8	2.0	-5.4	-3.4	% Change
Operating Income	5,960	6,313	6,343	6,632	5,222	4,281	Operating Income
% Change	30.8	5.9	0.5	4.6	-21.3	-18.0	% Change
Net Income	3,538	4,028	3,104	4,631	4,789	4,412	Net Income
Operating Cash Flow	5,218	6,880	4,684	7,007	7,234	6,002	Operating Cash Flow
Capital Spending	-1,046	-1,254	-1,068	-1,134	-1,213	-1,246	Capital Spending
Free Cash Flow	4,172	5,626	3,616	5,873	6,021	4,756	Free Cash Flow
% Sales	14.5	18.9	12.1	19.2	20.8	17.0	% Sales
EPS	2.48	2.89	2.27	3.41	3.54	3.26	EPS
% Change	2.9	16.5	-21.5	50.2	3.8	-7.9	% Change
Free Cash Flow/Share	3.39	3.68	3.14	3.58	4.93	3.52	Free Cash Flow/Share
Dividends/Share	1.52	1.72	1.84	2.00	2.16	2.20	Dividends/Share
Book Value/Share	36.32	36.06	37.09	37.17	38.63	37.41	Book Value/Share
Shares Outstanding (Mil)	1,406	1,373	1,353	1,343	1,340	1,344	Shares Outstanding (Mil)
Return on Equity %	6.7	7.9	6.2	9.2	9.5	8.8	Profitability
Return on Assets %	3.4	4.0	3.3	5.1	5.3	4.8	Return on Assets %
Net Margin %	12.3	13.6	10.4	15.2	16.6	15.8	Net Margin %
Asset Turnover	0.28	0.30	0.31	0.34	0.32	0.30	Asset Turnover
Financial Leverage	1.9	2.0	1.8	1.8	1.8	1.9	Financial Leverage
Gross Margin %	68.3	68.7	69.8	70.0	67.4	65.8	Gross Margin %
Operating Margin %	20.7	21.3	21.2	21.7	18.1	15.3	Operating Margin %
Long-Term Debt	30,221	25,898	23,678	24,476	21,976	22,822	Long-Term Debt
Total Equity	52,063	50,294	50,720	50,091	50,737	50,296	Total Equity
Fixed Asset Turns	6.0	6.5	6.7	6.6	6.1	5.8	Fixed Asset Turns

## Quarterly Revenue & EPS

	Jul	Oct	Jan	Apr	Total
Revenue (Mil)					
2020	7,493.0	7,706.0	7,717.0	5,997.0	28,913.0
2019	7,384.0	7,481.0	7,546.0	8,146.0	30,557.0
2018	7,390.0	7,050.0	7,369.0	8,144.0	29,953.0
2017	7,166.0	7,345.0	7,283.0	7,916.0	29,710.0
Earnings Per Share (€)					
2020	0.64	1.01	1.42	0.48	3.54
2019	0.79	0.82	0.94	0.87	3.41
2018	0.74	1.48	-1.03	1.07	2.27
2017	0.66	0.80	0.59	0.84	2.89

## Revenue Growth Year On Year %



# Research Methodology for Valuing Companies

## Qualitative Equity Research Overview

At the heart of our valuation system is a detailed projection of a company's future cash flows, resulting from our analysts' research. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into our globally standardized, proprietary discounted cash flow, or DCF, modeling templates. We use scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools to augment this process. We believe this bottom-up, long-term, fundamentally based approach allows our analysts to focus on long-term business drivers, which have the greatest valuation impact, rather than short-term market noise.

Morningstar's equity research group ("we," "our") believes that a company's intrinsic worth results from the future cash flows it can generate. The Morningstar Rating for stocks identifies stocks trading at an uncertainty-adjusted discount or premium to their intrinsic worth—or fair value estimate, in Morningstar terminology. Five-star stocks sell for the biggest risk-adjusted discount to their fair values whereas 1-star stocks trade at premiums to their intrinsic worth.

Four key components drive the Morningstar rating: (1) our assessment of the firm's economic moat, (2) our estimate of the stock's fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process ultimately culminates in our single-point star rating.

### 1. Economic Moat

The concept of an economic moat plays a vital role not only in our qualitative assessment of a firm's long-term investment potential, but also in the actual calculation of our fair value estimates. An economic moat is a structural feature that allows a firm to sustain excess profits over a long period of time. We define excess economic profits as returns on invested capital (or ROIC) over and above our estimate of a firm's cost of capital, or weighted average cost of capital (or WACC). Without a moat, profits are more susceptible to competition. We have identified five sources of economic moats:

intangible assets, switching costs, network effect, cost advantage, and efficient scale.

Companies with a narrow moat are those we believe are more likely than not to achieve normalized excess returns for at least the next 10 years. Wide-moat companies are those in which we have very high confidence that excess returns will remain for 10 years, with excess returns more likely than not to remain for at least 20 years. The longer a firm generates economic profits, the higher its intrinsic value. We believe low-quality no-moat companies will see their normalized returns gravitate toward the firm's cost of capital more quickly than companies with moats.

To assess the direction of the underlying competitive advantages, analysts perform ongoing assessments of the moat trend. A firm's moat trend is positive in cases where we think its sources of competitive advantage are growing stronger; stable where we don't anticipate changes to competitive advantages over the next several years; or negative when we see signs of deterioration.

All the moat and moat trend ratings undergo periodic review and any changes must be approved by the Morningstar Economic Moat Committee, comprised of senior members of Morningstar's equity research department.

### 2. Estimated Fair Value

Combining our analysts' financial forecasts with the firm's economic moat helps us assess how long returns on invested capital are likely to exceed the firm's cost of capital. Returns of firms with a wide economic moat rating are assumed to fade to the perpetuity period over a longer period of time than the returns of narrow-moat firms, and both will fade slower than no-moat firms, increasing our estimate of their intrinsic value.

Our model is divided into three distinct stages:

#### Stage I: Explicit Forecast

In this stage, which can last five to 10 years, analysts make full financial statement forecasts, including items such as revenue, profit margins, tax rates, changes in working-capital accounts, and capital spending. Based on these projections, we calculate earnings before interest, after taxes, or EBIT, and the net new investment, or NNI, to derive our annual free cash flow forecast.

#### Stage II: Fade


The second stage of our model is the period it will take the company's return on new invested capital—the return on capital of the next dollar invested ("RONIC")—to decline (or rise) to its cost of capital. During the Stage II period, we use a formula to approximate cash flows in lieu of explicitly modeling the income statement, balance sheet, and cash flow statement as we do in Stage I. The length of the second stage depends on the strength of the company's economic moat. We forecast this period to last anywhere from one year (for companies with no economic moat) to 10–15 years or more (for wide-moat companies). During this period, cash flows are forecast using four assumptions: an average growth rate for EBIT over the period, a normalized investment rate, average return on new invested capital, or RONIC, and the number of years until perpetuity, when excess returns cease. The investment rate and return on new invested capital decline until the perpetuity stage is reached. In the case of firms that do not earn their cost of capital, we assume marginal ROICs rise to the firm's cost of capital (usually attributable to less reinvestment), and we may truncate the second stage.

#### Stage III: Perpetuity

Once a company's marginal ROIC hits its cost of capital, we calculate a continuing value, using a standard perpetuity formula. At perpetuity, we assume that any growth or decline or investment in the business neither creates nor destroys value and that any new investment provides a return in line with estimated WACC.

Because a dollar earned today is worth more than a dollar earned tomorrow, we discount our projections of cash flows in stages I, II, and III to arrive at a total present value of expected future cash flows. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the WACC, which is a weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term market-value weights.

## Morningstar Research Methodology for Valuing Companies



# Research Methodology for Valuing Companies

## 3. Uncertainty Around That Fair Value Estimate

Morningstar's Uncertainty Rating captures a range of likely potential intrinsic values for a company and uses it to assign the margin of safety required before investing, which in turn explicitly drives our stock star rating system. The Uncertainty Rating represents the analysts' ability to bound the estimated value of the shares in a company around the fair value estimate, based on the characteristics of the business underlying the stock, including operating and financial leverage, sales sensitivity to the overall economy, product concentration, pricing power, and other company-specific factors.

Analysts consider at least two scenarios in addition to their base case: a bull case and a bear case. Assumptions are chosen such that the analyst believes there is a 25% probability that the company will perform better than the bull case, and a 25% probability that the company will perform worse than the bear case. The distance between the bull and bear cases is an important indicator of the uncertainty underlying the fair value estimate.

Our recommended margin of safety widens as our uncertainty of the estimated value of the equity increases. The more uncertain we are about the estimated value of the equity, the greater the discount we require relative to our estimate of the value of the firm before we would recommend the purchase of the shares. In addition, the uncertainty rating provides guidance in portfolio construction based on risk tolerance.

Our uncertainty ratings for our qualitative analysis are low, medium, high, very high, and extreme.


- ▶ Low—margin of safety for 5-star rating is a 20% discount and for 1-star rating is 25% premium.
- ▶ Medium—margin of safety for 5-star rating is a 30% discount and for 1-star rating is 35% premium.
- ▶ High—margin of safety for 5-star rating is a 40% discount and for 1-star rating is 55% premium.
- ▶ Very High—margin of safety for 5-star rating is a 50% discount and for 1-star rating is 75% premium.
- ▶ Extreme—margin of safety for 5-star rating is a 75% discount and for 1-star rating is 300% premium.

## 4. Market Price

The market prices used in this analysis and noted in the report come from exchange on which the stock is listed, which we believe is a reliable source.

For more details about our methodology, please go to <https://shareholders.morningstar.com>.

## Morningstar Equity Research Star Rating Methodology



## Morningstar Star Rating for Stocks

Once we determine the fair value estimate of a stock, we compare it with the stock's current market price on a daily basis, and the star rating is automatically re-calculated at the market close on every day the market on which the stock is listed is open.

Please note, there is no predefined distribution of stars. That is, the percentage of stocks that earn 5 stars can fluctuate daily, so the star ratings, in the aggregate, can serve as a gauge of the broader market's valuation. When there are many 5-star stocks, the stock market as a whole is more undervalued, in our opinion, than when very few companies garner our highest rating.

We expect that if our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years (although it is impossible to predict the exact time frame in which market prices may adjust).

Our star ratings are guideposts to a broad audience and individuals must consider their own specific investment goals, risk tolerance, tax situation, time horizon, income needs, and complete investment portfolio, among other factors.

The Morningstar Star Ratings for stocks are defined below:

★★★★★ We believe appreciation beyond a fair risk-adjusted return is highly likely over a multiyear time frame. The current market price represents an excessively pessimistic outlook, limiting downside risk and maximizing upside potential.

★★★★ We believe appreciation beyond a fair risk-adjusted return is likely.

★★★ Indicates our belief that investors are likely to receive a fair risk-adjusted return (approximately cost of equity).

★★ We believe investors are likely to receive a less than fair risk-adjusted return.

★ Indicates a high probability of undesirable risk-adjusted returns from the current market price over a multiyear time frame, based on our analysis. The market is pricing in an excessively optimistic outlook, limiting upside potential and leaving the investor exposed to Capital loss.



# Research Methodology for Valuing Companies

## Other Definitions

**Last Price:** Price of the stock as of the close of the market of the last trading day before date of the report.

**Stewardship Rating:** Represents our assessment of management's stewardship of shareholder capital, with particular emphasis on capital allocation decisions. Analysts consider companies' investment strategy and valuation, financial leverage, dividend and share buyback policies, execution, compensation, related party transactions, and accounting practices. Corporate governance practices are only considered if they've had a demonstrated impact on shareholder value. Analysts assign one of three ratings: "Exemplary," "Standard," and "Poor." Analysts judge stewardship from an equity holder's perspective. Ratings are determined on an absolute basis. Most companies will receive a Standard rating, and this is the default rating in the absence of evidence that managers have made exceptionally strong or poor capital allocation decisions.

**Quantitative Valuation:** Using the below terms, intended to denote the relationship between the security's Last Price and Morningstar's quantitative fair value estimate for that security.

- Undervalued: Last Price is below Morningstar's quantitative fair value estimate.
- Fairly Valued: Last Price is in line with Morningstar's quantitative fair value estimate.
- Overvalued: Last Price is above Morningstar's quantitative fair value estimate.

## Risk Warning

Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security investment return and an investor's principal value will fluctuate so that, when redeemed, an investor's shares may be worth more or less than their original cost. A security's current investment performance may be lower or higher than the investment performance noted within the report. Morningstar's Uncertainty Rating serves as a useful data point with respect to sensitivity analysis of the assumptions used in our determining a fair value price.

## Quantitative Equity Reports Overview

The quantitative report on equities consists of data, statistics and quantitative equity ratings on equity securities. Morningstar, Inc.'s quantitative equity ratings are forward looking and are generated by a statistical model that is based on Morningstar Inc.'s analyst-driven equity ratings and quantitative statistics. Given the nature of the

quantitative report and the quantitative ratings, there is no one analyst in which a given report is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative equity ratings used in this report. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities.

## Quantitative Equity Ratings

Morningstar's quantitative equity ratings consist of:

- (i) Quantitative Fair Value Estimate
  - (ii) Quantitative Star Rating
  - (iii) Quantitative Uncertainty
  - (iv) Quantitative Economic Moat
  - (v) Quantitative Financial Health
- (collectively the "Quantitative Ratings").

The Quantitative Ratings are calculated daily and derived from the analyst-driven ratings of a company's peers as determined by statistical algorithms. Morningstar, Inc. ("Morningstar," "we," "our") calculates Quantitative Ratings for companies whether it already provides analyst ratings and qualitative coverage. In some cases, the Quantitative Ratings may differ from the analyst ratings because a company's analyst-driven ratings can significantly differ from other companies in its peer group.

**Quantitative Fair Value Estimate:** Intended to represent Morningstar's estimate of the per share dollar amount that a company's equity is worth today. Morningstar calculates the quantitative fair value estimate using a statistical model derived from the fair value estimate Morningstar's equity analysts assign to companies. Please go to <https://shareholders.morningstar.com> for information about fair value estimates Morningstar's equity analysts assign to companies.

**Quantitative Economic Moat:** Intended to describe the strength of a firm's competitive position. It is calculated using an algorithm designed to predict the Economic Moat rating a Morningstar analyst would assign to the stock. The rating is expressed as Narrow, Wide, or None.

- Narrow: assigned when the probability of a stock receiving a "Wide Moat" rating by an analyst is greater than 70% but less than 99%.
- Wide: assigned when the probability of a stock receiving a "Wide Moat" rating by an analyst is greater than 99%.
- None: assigned when the probability of an analyst receiving a "Wide Moat" rating by an analyst is less than 70%.

**Quantitative Star Rating:** Intended to be the summary rating based on the combination of our Quantitative Fair

Value Estimate, current market price, and the Quantitative Uncertainty Rating. The rating is expressed as 1-Star, 2-Star, 3-Star, 4-Star, and 5-Star.

★: the stock is overvalued with a reasonable margin of safety.

Log (Quant FVE/Price) < -1 \* Quantitative Uncertainty

★★: the stock is somewhat overvalued.

Log (Quant FVE/Price) between (-1 \* Quantitative Uncertainty, -0.5 \* Quantitative Uncertainty)

★★★: the stock is approximately fairly valued.

Log (Quant FVE/Price) between (-0.5 \* Quantitative Uncertainty, 0.5 \* Quantitative Uncertainty)

★★★★: the stock is somewhat undervalued.

Log (Quant FVE/Price) between (0.5 \* Quantitative Uncertainty, 1 \* Quantitative Uncertainty)

★★★★★: the stock is undervalued with a reasonable margin of safety. Log (Quant FVE/Price) > 1 \* Quantitative Uncertainty

**Quantitative Uncertainty:** Intended to represent Morningstar's level of uncertainty about the accuracy of the quantitative fair value estimate. Generally, the lower the quantitative Uncertainty, the narrower the potential range of outcomes for that particular company. The rating is expressed as Low, Medium, High, Very High, and Extreme.

- Low: the interquartile range for possible fair values is less than 10%.
- Medium: the interquartile range for possible fair values is less than 15% but greater than 10%.
- High: the interquartile range for possible fair values is less than 35% but greater than 15%.
- Very High: the interquartile range for possible fair values is less than 80% but greater than 35%.
- Extreme: the interquartile range for possible fair values is greater than 80%.

**Quantitative Financial Health:** Intended to reflect the probability that a firm will face financial distress in the near future. The calculation uses a predictive model designed to anticipate when a company may default on its financial obligations. The rating is expressed as Weak, Moderate, and Strong.

- Weak: assigned when Quantitative Financial Health < 0.2
- Moderate: assigned when Quantitative Financial Health is between 0.2 and 0.7
- Strong: assigned when Quantitative Financial Health > 0.7

# Research Methodology for Valuing Companies

## Other Definitions

**Last Close:** Price of the stock as of the close of the market of the last trading day before date of the report.

**Quantitative Valuation:** Using the below terms, intended to denote the relationship between the security's Last Price and Morningstar's quantitative fair value estimate for that security.

- Undervalued: Last Price is below Morningstar's quantitative fair value estimate.
- Fairly Valued: Last Price is in line with Morningstar's quantitative fair value estimate.
- Overvalued: Last Price is above Morningstar's quantitative fair value estimate.

This Report has not been made available to the issuer of the security prior to publication.

## Risk Warning

Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security investment return and an investor's principal value will fluctuate so that, when redeemed, an investor's shares may be worth more or less than their original cost. A security's current investment performance may be lower or higher than the investment performance noted within the report.

The quantitative equity ratings are not statements of fact. Morningstar does not guarantee the completeness or accuracy of the assumptions or models used in determining the quantitative equity ratings. In addition, there is the risk that the price target will not be met due to such things as unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, and tax rate. For investments in foreign markets there are further risks, generally based on exchange rate changes or changes in political and social conditions.

A change in the fundamental factors underlying the quantitative equity ratings can mean that the valuation is subsequently no longer accurate.

For more information about Morningstar's quantitative methodology, please visit <http://global.morningstar.com/equitydisclosures>.

# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★	110.97 USD	118.00 USD	0.94	2.02	2.09	149.19	Medical Devices	Standard
23 Nov 2020 22:19, UTC	23 Nov 2020	18 Feb 2020 20:20, UTC		23 Nov 2020	23 Nov 2020	23 Nov 2020		

## General Disclosure

The analysis within this report is prepared by the person (s) noted in their capacity as an analyst for Morningstar's equity research group. The equity research group consists of various Morningstar, Inc. subsidiaries ("Equity Research Group"). In the United States, that subsidiary is Morningstar Research Services LLC, which is registered with and governed by the U.S. Securities and Exchange Commission.

The opinions expressed within the report are given in good faith, are as of the date of the report and are subject to change without notice. Neither the analyst nor Equity Research Group commits themselves in advance to whether and in which intervals updates to the report are expected to be made. The written analysis and Morningstar Star Rating for stocks are statements of opinions; they are not statements of fact.

The Equity Research Group believes its analysts make a reasonable effort to carefully research information contained in the analysis. The information on which the analysis is based has been obtained from sources believed to be reliable such as, for example, the company's financial statements filed with a regulator, company website, Bloomberg and any other the relevant press sources. Only the information obtained from such sources is made available to the issuer who is the subject of the analysis, which is necessary to properly reconcile with the facts. Should this sharing of information result in considerable changes, a statement of that fact will be noted within the report. While the Equity Research Group has obtained data, statistics and information from sources it believes to be reliable, neither the Equity Research Group nor Morningstar, Inc. performs an audit or seeks independent verification of any of the data, statistics, and information it receives.

## General Quantitative Disclosure

The Quantitative Equity Report ("Report") is derived from data, statistics and information within Morningstar, Inc.'s database as of the date of the Report and is subject to change without notice. The Report is for informational purposes only, intended for financial professionals and/or sophisticated investors ("Users") and should not be the sole piece of information used by such Users or their clients in making an investment decision. The quantitative equity ratings noted the Report are provided in good faith, are as of the date of

Price/Fair Value Morningstar data as of Nov 23, 2020



the Report and are subject to change. While Morningstar has obtained data, statistics and information from sources it believes to be reliable, Morningstar does not perform an audit or seeks independent verification of any of the data, statistics, and information it receives.

The quantitative equity ratings are not a market call, and do not replace the User or User's clients from conducting their own due-diligence on the security. The quantitative equity rating is not a suitability assessment; such assessments take into account may factors including a person's investment objective, personal and financial situation, and risk tolerance all of which are factors the quantitative equity rating statistical model does not and did not consider.

Prices noted with the Report are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

## General Disclosure (applicable to both Quantitative and Qualitative Research)

Unless otherwise provided in a separate agreement, recipients accessing this report may only use it in the country in which the Morningstar distributor is based. Unless stated otherwise, the original distributor of the report is Morningstar Research Services LLC, a U.S.A. domiciled financial institution.

This report is for informational purposes only and has no regard to the specific investment objectives,

financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: recipients must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.

The information, data, analyses and opinions presented herein are not warranted to be accurate, correct, complete or timely. Unless otherwise provided in a separate agreement, neither Morningstar, Inc. or the Equity Research Group represents that the report contents meet all of the presentation and/or disclosure standards applicable in the jurisdiction the recipient is located.

Except as otherwise required by law or provided for in a separate agreement, the analyst, Morningstar, Inc. and the Equity Research Group and their officers, directors and employees shall not be responsible or liable for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions within the report. The Equity Research Group encourages recipients of this report to read all relevant issue documents (e.g., prospectus) pertaining to the security concerned, including without limitation, information relevant to its investment objectives, risks, and costs before making an

# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★	110.97 USD	118.00 USD	0.94	2.02	2.09	149.19	Medical Devices	Standard
23 Nov 2020 22:19, UTC	23 Nov 2020	18 Feb 2020 20:20, UTC		23 Nov 2020	23 Nov 2020	23 Nov 2020		

investment decision and when deemed necessary, to seek the advice of a legal, tax, and/or accounting professional.

The Report and its contents are not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Morningstar, Inc. or its affiliates to any registration or licensing requirements in such jurisdiction.

Where this report is made available in a language other than English and in the case of inconsistencies between the English and translated versions of the report, the English version will control and supersede any ambiguities associated with any part or section of a report that has been issued in a foreign language. Neither the analyst, Morningstar, Inc., or the Equity Research Group guarantees the accuracy of the translations.

This report may be distributed in certain localities, countries and/or jurisdictions ("Territories") by independent third parties or independent intermediaries and/or distributors ("Distributors"). Such Distributors are not acting as agents or representatives of the analyst, Morningstar, Inc. or the Equity Research Group. In Territories where a Distributor distributes our report, the Distributor is solely responsible for complying with all applicable regulations, laws, rules, circulars, codes and guidelines established by local and/or regional regulatory bodies, including laws in connection with the distribution third-party research reports.

## Conflicts of Interest:

- No interests are held by the analyst with respect to the security subject of this investment research report. – Morningstar, Inc. may hold a long position in the security subject of this investment research report that exceeds 0.5% of the total issued share capital of the security. To determine if such is the case, please click <http://msi.morningstar.com> and <http://mdi.morningstar.com>.
- Analysts' compensation is derived from Morningstar, Inc.'s overall earnings and consists of salary, bonus and in some cases restricted stock.

- Neither Morningstar, Inc. or the Equity Research Group receives commissions for providing research nor do they charge companies to be rated.

- Neither Morningstar, Inc. or the Equity Research Group is a market maker or a liquidity provider of the security noted within this report.

- Neither Morningstar, Inc. or the Equity Research Group has been a lead manager or co-lead manager over the previous 12-months of any publicly disclosed offer of financial instruments of the issuer.

- Morningstar, Inc.'s investment management group does have arrangements with financial institutions to provide portfolio management/investment advice some of which an analyst may issue investment research reports on. However, analysts do not have authority over Morningstar's investment management group's business arrangements nor allow employees from the investment management group to participate or influence the analysis or opinion prepared by them.

- Morningstar, Inc. is a publically traded company (Ticker Symbol: MORN) and thus a financial institution the security of which is the subject of this report may own more than 5% of Morningstar, Inc.'s total outstanding shares. Please access Morningstar, Inc.'s proxy statement, "Security Ownership of Certain Beneficial Owners and Management" section <https://shareholders.morningstar.com/investor-relations/financials/sec-filings/default.aspx>

- Morningstar, Inc. may provide the product issuer or its related entities with services or products for a fee and on an arms' length basis including software products and licenses, research and consulting services, data services, licenses to republish our ratings and research in their promotional material, event sponsorship and website advertising.

Further information on Morningstar, Inc.'s conflict of interest policies is available from <http://global.morningstar.com/equitydisclosures>. Also, please note analysts are subject to the CFA Institute's Code of Ethics and Standards of Professional Conduct.

For a list of securities which the Equity Research Group

currently covers and provides written analysis on please contact your local Morningstar office. In addition, for historical analysis of securities covered, including their fair value estimate, please contact your local office.

**For Recipients in Australia:** This Report has been issued and distributed in Australia by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544; ASFL: 240892). Morningstar Australasia Pty Ltd is the provider of the general advice ('the Service') and takes responsibility for the production of this report. The Service is provided through the research of investment products. To the extent the Report contains general advice it has been prepared without reference to an investor's objectives, financial situation or needs. Investors should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement before making any decision to invest. Refer to our Financial Services Guide (FSG) for more information at <http://www.morningstar.com.au/fsg.pdf>.

**For Recipients in Canada:** This research is not prepared subject to Canadian disclosure requirements.

**For Recipients in Hong Kong:** The Report is distributed by Morningstar Investment Management Asia Limited, which is regulated by the Hong Kong Securities and Futures Commission to provide services to professional investors only. Neither Morningstar Investment Management Asia Limited, nor its representatives, are acting or will be deemed to be acting as an investment advisor to any recipients of this information unless expressly agreed to by Morningstar Investment Management Asia Limited. For enquiries regarding this research, please contact a Morningstar Investment Management Asia Limited Licensed Representative at <http://global.morningstar.com/equitydisclosures>.

**For Recipients in India:** This Investment Research is issued by Morningstar Investment Adviser India Private Limited. Morningstar Investment Adviser India Private Limited is registered with the Securities and Exchange Board of India (Registration number INA00001357) and provides investment advice and research. Morningstar Investment Adviser India Private Limited has not been the subject of any disciplinary action by

# Medtronic PLC MDT (XNYS)

Morningstar Rating	Last Price	Fair Value Estimate	Price/Fair Value	Trailing Dividend Yield %	Forward Dividend Yield %	Market Cap (Bil)	Industry	Stewardship
★★★	110.97 USD	118.00 USD	0.94	2.02	2.09	149.19	Medical Devices	Standard
23 Nov 2020 22:19, UTC	23 Nov 2020	18 Feb 2020 20:20, UTC		23 Nov 2020	23 Nov 2020	23 Nov 2020		

SEBI or any other legal/regulatory body. Morningstar Investment Adviser India Private Limited is a wholly owned subsidiary of Morningstar Investment Management LLC. In India, Morningstar Investment Adviser India Private Limited has one associate, Morningstar India Private Limited, which provides data related services, financial data analysis and software development.

The Research Analyst has not served as an officer, director or employee of the fund company within the last 12 months, nor has it or its associates engaged in market making activity for the fund company.

\*The Conflicts of Interest disclosure above also applies to relatives and associates of Manager Research Analysts in India # The Conflicts of Interest disclosure above also applies to associates of Manager Research Analysts in India. The terms and conditions on which Morningstar Investment Adviser India Private Limited offers Investment Research to clients, varies from client to client, and are detailed in the respective client agreement.

**For recipients in Japan:** The Report is distributed by Ibbotson Associates Japan, Inc., which is regulated by Financial Services Agency. Neither Ibbotson Associates Japan, Inc., nor its representatives, are acting or will be deemed to be acting as an investment advisor to any recipients of this information.

**For recipients in Singapore:** This Report is distributed by Morningstar Investment Adviser Singapore Pte Limited, which is licensed by the Monetary Authority of Singapore to provide financial advisory services in Singapore. Investors should consult a financial adviser regarding the suitability of any investment product, taking into account their specific investment objectives, financial situation or particular needs, before making any investment decisions.